$250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in Dividends
π AbbVie raised its quarterly dividend by approximately 5.2% from $1.73 to $1.82, payable February 16, 2027.
π° The new annualized dividend rate of $7.28 covers about 52% of the company's adjusted EPS guidance of $13.95 to $13.99.
π Skyrizi revenue grew 22.7% to $5.78 billion in Q3, while Rinvoq rose 23.9%, offsetting a 31.2% drop in Humira sales.
π AbbVie retains its spot in the S&P Dividend Aristocrats Index due to a consistent record of annual dividend raises.
π Q3 adjusted EPS of $2.49 beat the consensus estimate of $2.09, excluding one-time deal charges.
π‘οΈ The company's dividend safety is bolstered by strong growth in immunology and neuroscience segments replacing legacy revenue.
Bullish Signals
- AbbVie increased its quarterly dividend by approximately 5.2% to $1.82, signaling confidence in future cash flows.
- The company's Q3 adjusted EPS of $2.49 beat the consensus estimate of $2.09, demonstrating strong operational performance.
- Skyrizi and Rinvoq drove significant revenue growth in Q3, with Skyrizi up 22.7% and Rinvoq up 23.9%, successfully replacing Humira as growth engines.
- AbbVie maintains its S&P Dividend Aristocrat status, highlighting a long-term track record of increasing dividends annually.
- The new dividend payout covers roughly 52% of adjusted EPS guidance, providing a wide safety margin compared to peers.
Risk Factors
- AbbVie faces ongoing revenue pressure from Humira as cheaper biosimilars continue to take significant market share.
- The company's growth strategy relies heavily on the successful transition to Skyrizi and Rinvoq, which must sustain high growth rates.
Full Analysis
AbbVie (ABBV) recently announced a quarterly dividend increase of approximately 5.2%, raising the payout from $1.73 to $1.82 per share, with the next payment scheduled for February 16, 2027. This adjustment brings the new annualized dividend rate to $7.28, which covers roughly 52% of the company's raised adjusted EPS guidance ranging between $13.95 and $13.99.
The pharmaceutical giant is successfully transitioning its revenue base as Skyrizi and Rinvoq have replaced Humira as primary growth drivers. In the third quarter, Skyrizi revenue grew 22.7% to $5.78 billion while Rinvoq rose 23.9%, effectively offsetting a 31.2% decline in Humira sales driven by cheaper biosimilars taking market share.
AbbVie maintains its status as an S&P Dividend Aristocrat, reflecting a long history of annual dividend increases. The company's financial position is supported by strong growth in immunology and neuroscience segments, providing a wide cushion compared to peers like Pfizer whose dividends have remained frozen since early 2025.